Roche’s announcement of a lower offer for the remaining shares of DNA makes me want to abandon this play. They (Roche) are having earnings trouble and in my opinion, this is a last gasp to try and acquire DNA while they still can get financing (and that’s already in question, as I wrote about here). [...]
Is 3Com going to spin off it’s cash cow again? (last time it was Palm). Research shows that recently hired TippingPoint (a 3Com company) President Alan Kessler was once hired as Palm’s president in 1999 by 3Com when it still owned Palm. Three months later, 3Com spun off Palm. Now he’s back at another 3Com [...]
Well, it’s not an all cash deal, so this one is a little more tricky. Now PFE’s stock price is part of the equation:
“The New York-based company will pay $50.19 — $33 in cash and 0.985 share of its stock — for each Wyeth share. That represents a 29 percent premium over Wyeth’s closing share [...]
Pfizer Inc. (PFE) said it is in talks to buy Wyeth (WYE). WSJ reports that they have been talking for months now and are not close to a deal yet:
“The two sides have been in discussions for months and a deal isn’t imminent, the people said. Given recent market volatility and overall economic uncertainty, the [...]
FRME announced that it completed the LNCB merger successfully on Dec. 31, 2008.
Here’s how I made out on the deal:
I get to choose either:
0.7004 shares of FRME for each of my LNCB. $22.21 * 0.7004 = $15.56. IOW, $15.56 for each share of LNCB if I sell my FRME stock soon after the deal [...]
Drugmaker Elan (ELN) said it wants to merge with someone and has hired advisers (Citigroup Global Markets) to review their options. Elan is Ireland’s largest drugmaker.
It is reviewing options such as a “…minority investment, an alliance, or a merger or sale of the company.”
The stock has been down and critics blame weak sales and company [...]
Abbott said it is buying Advanced Medical Optics (EYE) for $22/sh. EYE’s shares jumped from $8.85 on Friday to a current $21.44 today. Not much of an arbitrage scenario here, but I’ll keep an eye on it.
RE: Rohm & Haas Co. (ROH) by Dow Chemical Co. (DOW)
Acquirer: DOW
Target: ROH
Offer per share: $78 cash
Target share price: $56.76
Expected closing: 1/15/2009
ROI: 37.42%
Annualized gain: off the charts
The reason for the huge gap is the dumping of the Kuwait/DOW partnership this past weekend. Many feel the deal for ROH will get cancelled, since DOW was counting [...]
Well, looks like I am going to lose on my decision to buy HUN for the short term. They announced the deal was killed today, with Hexion paying break fees to HUN ($750M cash, $250M notes).
I went against my gut and held, when I should have sold earlier (I wrote about maybe getting out of [...]
It’s official… atleast as far as current shareholders are concerned. They approved the deal recently and looks like it will close no later than Jan 7, 2009. That’s good news for me, as my entry point shows here:
Entry Price: $65.34
Deal Price: $69.50
My ROI will be: 6.4% (27.6% annualized if it close on Jan 7, 2009)
Source:
Press [...]
